Celldex Therapeutics, Inc. announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodularis (PN) has been accepted as an oral presentation at the 12th World Congress on Itch (WCI), being held in Miami on Nov. 5-7, 2023. The Phase 1b multi-center, randomized, double-blind, placebo-controlled trial is designed to study barzolvolimabin patients with prurigo nodularityis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.47 USD | -1.60% | -6.49% | -0.48% |
May. 06 | Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q1 Revenue $156,000 | MT |
May. 06 | Celldex Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.48% | 2.6B | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+43.45% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- CLDX Stock
- News Celldex Therapeutics, Inc.
- Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1B Results in Prurigo Nodularis At 12Th World Congress on Itch 2023